Skip to main content
Skip to Footer

American Journal of Psychiatry

  • Volume 178
  • Number 7
  • July 2021

Editor’s Note

Editorials

Clinical Case Conference

Reviews and Overviews

Publication date: 18 February 2021

Pages611–624

Objective: The authors sought to identify scalable evidence-based suicide prevention strategies. Methods: A search of PubMed and Google Scholar identified 20,234 articles published between September 2005 and December 2019, of which 97 were randomized ...

https://doi.org/10.1176/appi.ajp.2020.20060864

Articles

Publication date: 26 April 2021

Pages625–634

Objective: Socioeconomic factors have been suggested to influence the effect of education- and intelligence-associated genetic variants. However, results from previous studies on the interaction between socioeconomic status and education or intelligence ...

https://doi.org/10.1176/appi.ajp.2020.20040462

Publication date: 26 April 2021

Pages635–642

Objective: Public stigma is a barrier to care and increases the duration of untreated psychosis among individuals with first-episode psychosis. The authors recently demonstrated the efficacy of a 90-second social contact–based video intervention in ...

https://doi.org/10.1176/appi.ajp.2020.20091293

Publication date: 26 April 2021

Pages643–650

Objective: The Z-drugs (zolpidem, zopiclone, zaleplon) are widely used to treat insomnia in patients receiving prescription opioids, and the risk of overdose resulting from this coprescription has not been explored. The authors compared the rates of ...

https://doi.org/10.1176/appi.ajp.2020.20071038

Publication date: 03 March 2021

Pages651–659

Objective: Persons with opioid use disorder who take benzodiazepines are at high risk for overdose. The objective of this study was to evaluate the association of benzodiazepine and Z-drug use with drug-related poisonings among patients receiving ...

https://doi.org/10.1176/appi.ajp.2020.20081174

Publication date: 25 June 2021

Pages660–671

Objective: Sublingual buprenorphine-naloxone and extended-release injection naltrexone are effective treatments, with distinct mechanisms, for opioid use disorder. The authors examined whether patients’ demographic and clinical characteristics were ...

https://doi.org/10.1176/appi.ajp.2020.20060816

Correction

Past Issues

View Issues Archive
No.11
View Issue
1 Nov 2024

Vol. 181 | No. 11

No.10
View Issue
1 Oct 2024

Vol. 181 | No. 10

No.9
View Issue
1 Sep 2024

Vol. 181 | No. 9

No.8
View Issue
1 Aug 2024

Vol. 181 | No. 8